New oral anti coagulants – A guide for Plastic Surgeons
Main Article Content
Abstract
With the advent of new oral anticoagulants (NOACs), it is a challenge for a plastic surgeon to stay updated with the myriad of new medications, and their associated mechanisms of action, laboratory monitoring, adverse events and potential reversal agents. The limitations of warfarin therapy include varying pharmacokinetic profiles, multitude of food and drug interactions, hypersensitivity, resistance, therapy failure and frequent laboratory monitoring)1. Hence there are an increasing number of patients who are presenting to their plastic surgeon on alterative antithrombotic agents. The aim of this paper is to educate Plastic Surgeons regarding NOAC's, and their management in the operative setting.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2) Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-92.
3) Kraft CT, Bellile E, Baker SR, Kim JC, Moyer JS. Anticoagulant Complications in Facial Plastic and Reconstructive Surgery. JAMA Facial Plast Surg. 2015;17(2):103-107.
4) Hillman RS, Ault KA. Hematology in clinical practice. 2nd ed. New York: McGraw-Hill; 1998. Levy JH, Key NS, Azran MS. Novel oral anticoagulants: implications in the perioperative setting. Anesthesiology 2010;113:726-45.
5) Di Nisio M, Middeldorp S, Buller HR. Direct thrombin inhibitors. N Engl J Med 2005;353:1028-40.
6) Cotton BA, McCarthy JJ, Holcomb JB. Acutely injured patients on dabigatran. N Engl J Med 2011;365:2039-40.
7) Douketis JD. Pharmacologic properties of the new oral anticoagulants: a clinician-oriented review with a focus on perioperative management. Curr Pharm Des 2010;16: 3436-41
8) Massicotte, Anne. “A Practice Tool for the New Oral Anticoagulants.” Canadian Pharmacists Journal : CPJ 147.1 (2014): 25–32. PMC. Web. 26 Apr. 2016.
9) Spyropoulos AC. Brave new world: the current and future use of novel anticoagulants. Thromb Res 2008;123(Suppl 1):S29-35
10) Kumar, S., & Moorthy, R. (2016). New oral anticoagulants-a guide for ENT surgeons. The Journal of laryngology and otology, 130(4), 324-328.
11) Latona, J., & Rahman, A. (2015). Management of oral anticoagulation in the surgical patient. ANZ journal of surgery, 85(9), 620-625.
12) Eikelboom, J., & Merli, G. (2016). Bleeding with direct oral anticoagulants vs warfarin: clinical experience. The American Journal of Emergency Medicine.
13) Pinho-Gomes, A. C., Hague, A., & Ghosh, J. (2016). Management of novel oral anticoagulants in emergency and trauma surgery. The Surgeon.
14) Siegal, Deborah M., and Adam Cuker. "Reversal of novel oral anticoagulants in patients with major bleeding." Journal of thrombosis and thrombolysis 35.3 (2013): 391-398.
15) Spyropoulos AC, Douketis JD. How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood 2012;120:2954-62
New Oral Anti Coagulants – A guide for Plastic Surgeons